Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.
Looking for a particular Aspect Biosystems employee's phone or email?
The Aspect Biosystems annual revenue was $28.5 million in 2026.
Tamer Mohamed is the Founder and CEO of Aspect Biosystems.
89 people are employed at Aspect Biosystems.
Aspect Biosystems is based in Vancouver, British Columbia.
The NAICS codes for Aspect Biosystems are [5417, 541713, 541714, 54171, 541, 54].
The SIC codes for Aspect Biosystems are [87, 873].